The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use
Related Experiment Video
Updated: Jun 23, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Stephanie C Manson1, Ruth E Brown, Annamaria Cerulli
1United BioSource Corporation, 20 Bloomsbury Square, London WCIA 2NS, UK. stephanie.manson@unitedbiosource.com
Abstract:
Oral corticosteroids (OCS) are a key part of therapy regimens for a diverse variety of conditions. Despite their efficacy, they are associated with a wide variety of adverse events. The purpose of this review was to identify the range of adverse events that have been reported to be related to oral corticosteroids, examine the factors that influence their incidence and estimate the economic burden caused by these adverse events. In 61 identified studies, 21 different categories of OCS related adverse events were reported with increased fracture risk being the category most frequently described. Most studies that examined factors linked to the incidence of OCS related adverse events found that dose, age, gender, duration of use, treatment history, smoking habits or cholesterol level were influential in determining risk. Additionally, a cumulative economic analysis of selected adverse events found the annual cost of treating these events in the UK to be at least 165 pounds per patient taking OCS. The clinical and economic burden of OCS related adverse events highlights the need for OCS sparing therapies to be developed.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology
Dosage Regimen: Multiple Oral Dosage